Back to top
more

Mesoblast Limited (MESO)

(Real Time Quote from BATS)

$6.26 USD

6.26
271,556

+0.11 (1.79%)

Updated Apr 26, 2024 03:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for MESO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Mesoblast Limited falls in the month of June.

All items in Millions except Per Share data.

6/30/2023 6/30/2022 6/30/2021 6/30/2020 6/30/2019
Assets          
Cash & Equivalents 71 60 137 129 50
Receivables 7 4 5 2 4
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 3 5 7 6 8
Total Current Assets 82 70 148 137 63
Net Property & Equipment 1 2 3 2 1
Investments & Advances 2 2 2 2 2
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 577 579 581 582 583
Deposits & Other Assets 2 2 2 3 3
Total Assets 669 662 745 734 652
Liabilities & Shareholders Equity 6/30/2023 6/30/2022 6/30/2021 6/30/2020 6/30/2019
Notes Payable 0 0 0 0 0
Accounts Payable 20 23 20 25 13
Current Portion Long-Term Debt 6 5 53 32 14
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 12 20 19 29 17
Total Current Liabilities 42 51 94 90 44
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 1 11
Convertible Debt 0 0 0 0 0
Long-Term Debt 103 92 41 57 67
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 19 15 20 30 48
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 168 165 163 184 171
Shareholders Equity 6/30/2023 6/30/2022 6/30/2021 6/30/2020 6/30/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1,249 1,165 1,163 1,051 910
Capital Surplus 0 0 0 0 0
Retained Earnings -821 -739 -648 -549 -470
Other Equity 74 71 66 47 41
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 502 497 581 549 481
Total Liabilities & Shareholder's Equity 669 662 745 734 652
Total Common Equity 502 497 581 549 481
Shares Outstanding 81.40 65.00 64.80 58.40 49.80
Book Value Per Share 6.17 7.65 8.97 9.41 9.66

Fiscal Year End for Mesoblast Limited falls in the month of June.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 -99,921 -99,999 71 49
Receivables NA 4 NA 7 8
Notes Receivable NA NA NA 0 0
Inventories NA NA NA 0 0
Other Current Assets NA 4 NA 3 4
Total Current Assets NA 85 NA 82 61
Net Property & Equipment NA 1 NA 1 1
Investments & Advances NA 1 NA 2 2
Other Non-Current Assets NA NA NA 0 0
Deferred Charges NA NA NA 0 0
Intangibles NA 577 NA 577 578
Deposits & Other Assets NA 2 NA 2 2
Total Assets NA 670 NA 669 650
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA NA NA 0 0
Accounts Payable NA 11 NA 20 21
Current Portion Long-Term Debt NA 9 NA 6 7
Current Portion Capital Leases NA NA NA 0 0
Accrued Expenses NA NA NA 0 0
Income Taxes Payable NA NA NA 0 0
Other Current Liabilities NA 9 NA 12 22
Total Current Liabilities NA 31 NA 42 54
Mortgages NA NA NA 0 0
Deferred Taxes/Income NA NA NA 0 0
Convertible Debt NA NA NA 0 0
Long-Term Debt NA 107 NA 103 99
Non-Current Capital Leases NA NA NA 0 0
Other Non-Current Liabilities NA NA 19 11
Minority Interest (Liabilities) NA NA NA 0 0
Total Liabilities NA 162 NA 168 168
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA NA NA 0 0
Common Stock (Par) NA 1,286 NA 1,249 1,208
Capital Surplus NA NA NA 0 0
Retained Earnings NA -853 NA -821 -799
Other Equity NA 76 NA 74 74
Treasury Stock NA NA NA 0 0
Total Shareholder's Equity NA 509 NA 502 482
Total Liabilities & Shareholder's Equity NA 670 NA 669 650
Total Common Equity 0 100,508 0 502 482
Shares Outstanding 114.00 101.50 81.40 81.40 73.70
Book Value Per Share 0.00 990.22 0.00 6.17 6.54